Loading...
Identification and Characterization of IMD-0354 as a Glutamine Carrier Protein Inhibitor in Melanoma
A key hallmark of cancer, altered metabolism, is central to cancer pathogenesis and therapy resistance. Robust glutamine metabolism is among cellular processes regulating tumor progression and responsiveness to therapy in a number of cancers, including melanoma and breast cancer. Among mechanisms un...
Saved in:
| Published in: | Mol Cancer Ther |
|---|---|
| Main Authors: | , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
2021
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC8102370/ https://ncbi.nlm.nih.gov/pubmed/33632871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-20-0354 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|